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ABSTRACT
MicroRNAs play important roles in many biological
processes. Their aberrant expression can have onco-
genic or tumor suppressor function directly partici-
pating to carcinogenesis, malignant transformation,
invasiveness and metastasis. Indeed, miRNA profiles
can distinguish not only between normal and cancer-
ous tissue but they can also successfully classify dif-
ferent subtypes of a particular cancer. Here, we focus
on a particular class of transcripts encoding poly-
cistronic miRNA genes that yields multiple miRNA
components. We describe ‘clustered MiRNA Master
Regulator Analysis (ClustMMRA)’, a fully redesigned
release of the MMRA computational pipeline (MiRNA
Master Regulator Analysis), developed to search for
clustered miRNAs potentially driving cancer molecu-
lar subtyping. Genomically clustered miRNAs are fre-
quently co-expressed to target different components
of pro-tumorigenic signaling pathways. By applying
ClustMMRA to breast cancer patient data, we iden-
tified key miRNA clusters driving the phenotype of
different tumor subgroups. The pipeline was applied
to two independent breast cancer datasets, provid-
ing statistically concordant results between the two
analyses. We validated in cell lines the miR-199/miR-
214 as a novel cluster of miRNAs promoting the triple
negative breast cancer (TNBC) phenotype through its
control of proliferation and EMT.
INTRODUCTION
MicroRNAs (miRNAs) are small RNAmolecules emerged
as important regulators of gene expression at the post-
transcriptional level. They have been shown to be involved
in the regulation of all essential functions of the cells
fromdifferentiation and proliferation to apoptosis (1). Each
miRNA possesses hundreds of target genes, and a single
gene can be targeted by several miRNAs (2), giving rise to
complex interaction networks, currently very partially char-
acterized.
Multiple studies demonstrated the importance of miR-
NAs in all the cancer hallmarks defined by Hanahan and
Weinberg (3) and indicated that they might function as
oncogenes or tumor suppressors (4–6). Further experimen-
tal evidences suggested that specific miRNAsmay also have
a role beyond the cancer onset and directly participate in
cancer invasiveness and metastasis (5,7). Indeed, miRNA
profiles can distinguish not only between normal and can-
cerous tissue but they can also successfully classify different
subtypes of a particular cancer (8,9), notably of breast can-
cer (10–12).
In this work, we focused our attention on a particular
class of transcripts encoding polycistronic miRNA genes
that yields multiple miRNA components. A famous exam-
ple of this class of transcripts is the mir-17/92 polycistronic
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oncogene that plays a role in the development of vari-
ous cancer types, especially in their most aggressive form
(13). Genomically clustered miRNAs of mir-17/92 are si-
multaneously expressed and target different components of
the signaling cascade as well as the downstream effectors
of pro-tumorigenic signaling pathways (14–16). Deep se-
quencing of triple negative breast cancer (TNBC) samples
revealed a threefold increase ofmiR-17/92 levels (11). Other
studies in breast cancer have shown that mir-106b/25 clus-
ter activates TGF- signaling and epithelial-mesenchymal
transition (EMT) (17) andmiR-221/222 cluster is a key reg-
ulator of luminal breast cancer tumor progression (18).
Since >30% of annotated human miRNAs are orga-
nized in genomic clusters, we can expect to find other
oncogenic/tumor suppressor polycistronic miRNAs that
are co-expressed to jointly regulate molecular pathways in-
volved in cancer malignancy. Existing computational ap-
proaches for the identification of master miRNA regula-
tors involved in cancer onset and subtyping are typically de-
signed to detect the effect of a single miRNA (see review in
(19)). However, miRNAs have been shown to frequently act
in a combined manner, jointly regulating proteins in close
proximity of the protein-protein interaction network (20)
and functionally related genes (21–25). The underlying as-
sumption of this work is that this mode of action might be
true also for genomically clustered miRNAs. Indeed, it has
already been shown that clustered miRNAs carry out per-
vasive cotargeting (26).
Here, we present Clustered MiRNA Master Regula-
tor Analysis (ClustMMRA), a fully redesigned release of
the MiRNA Master Regulator Analysis (MMRA) (27,28)
pipeline, developed to search for clustered miRNAs poten-
tially driving cancer subtyping. MMRA was designed for
miRNA underlying tumor subtypes, a comparison charac-
terized by much lower variation than cancer versus normal
conditions. The results of the MMRA pipeline were exper-
imentally validated, proposing a set of four miRNAs pre-
dicted to drive the stem-like aggressive colorectal cancer
subtype (27).
ClustMMRA extends MMRA to a model in which mul-
tiple miRNAs belonging to the same genomic cluster coor-
dinately target functionally related genes driving the pheno-
type of a particular cancer subtype. As theMMRApipeline,
ClustMMRA is a multi-step workflow that requires in in-
put miRNA/mRNA expression profiles from matched tu-
mor samples classified in different subtypes according to
subtype-specific gene signatures. The final output of Clust-
MMRA provides key miRNA clusters contributing to the
regulation of particular subtypes of the disease.
We tested this novel pipeline to search for
oncogenic/tumor suppressor polycistronic miRNAs
driving breast cancer subtypes. ClustMMRA was applied
to two independent breast cancer datasets whose samples
were previously classified into four subtypes (luminal A,
luminal B, HER2+ and triple negative). We obtained
statistically concordant results between the two analyses,
identifying five clusters of miRNAs with aberrant expres-
sion in a specific subtype of both datasets. Among them,
miR-199a/214 on chromosome 1 was found to be down-
regulated in the triple negative subtype and associated
to EMT regulation. Functional validation in cell lines
confirms the regulatory effect of this cluster in shaping
the triple negative subtype phenotype through its control
of proliferation and EMT. Overall, our computational
pipeline and experimental validations characterize a new
genomic cluster of miRNAs implicated in the TNBC
phenotype that might be further explored in diagnosis and
therapeutic strategies. In addition, we evinced a coopera-
tive mechanism for the regulatory activity of genomically
clustered miRNAs.
MATERIALS AND METHODS
MiRNA cluster annotation
The genomic locations of miRNAs were retrieved from
miRBase v18 (29). As in (30,31), co-clustered miRNAs are
defined asmiRNA genes located within 10 kb of distance on
the same chromosome and in the same strand.
Datasets preprocessing
Breast cancer (BRCA) RNA-seq and miRNA-seq Level
3 expression profiles were downloaded from The Cancer
Genome Atlas (TCGA) in January 2016. Only those pri-
mary tumors profiled for both mRNA and miRNA ex-
pression were included in the analysis, obtaining a total
of 397 samples. Two expression matrices (one for mRNAs
and the second for miRNAs) were normalized obtaining
the pairedmRNA/miRNA expression dataset here referred
to as TCGA. The Curie dataset was generated with mi-
croarray technologies (Agilent miRNA microarray kit V3
for miRNAs and Affymetrix U133plus2 for mRNA) and
pre-processed following the procedure described in (32). Ex-
periments were conducted in agreement with the Bioethic
Law No. 2004–800 and the Ethic Charter from the French
National Institute of Cancer (INCa), and after approval of
the ethics committee of our Institution. Finally the paired
microRNA-mRNA expression dataset of colorectal cancer
was downloaded from (27).
Definition of a gene signature for each breast cancer subtype
The ClustMMRA pipeline requires as input a gene sig-
nature for each disease subtype. Available signatures for
breast cancer subtypes, such as the PAM50 (33), were not
applicable here due to their limited size in terms of number
of genes. We thus defined the signatures for our breast
cancer study using the approach proposed in (34). The
Curie dataset was used for signature construction, while
the TCGA dataset was employed for signature validation.
Differential gene expression for each subtype vs. all the
other samples was computed by Student’s t-test and log
fold change cutoff (t-test adjusted P-value < 0.05 and
absolute(log fold change) > 0.5). Moreover, to increase
the predictive power of the constructed signatures, those
genes associated to more than one class according to
the previous criteria, or having a difference between the
first and second highest absolute(log fold changes) lower
than 0.2 were discarded. The choice of thresholds was
optimized to maximize the gene association to a unique
subtype and the number of genes included in each signature
(on average 117 genes per signature). For each subtype,
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Figure 1. Schematic representation of the Clustered microRNA Master
Regulator Analysis (ClustMMRA) workflow. The schema reports the data
required as initial input, the four analytical steps with the respective out-
puts, and the final output of the pipeline.
two separated signatures were defined (‘down’ and ‘up’),
based on the sign of the expression change of their genes.
The .gmt file of the constructed signatures is available at
https://github.com/lcan88/Supplementary miRNA cluster/
blob/master/signature Breast.gmt. The reliability of these
signatures were tested in two ways. First, their classifi-
cation performances were validated on TCGA data. We
classified the TCGA samples using our signatures with the
Nearest Template Prediction (NTP) method (35), as done
in (36,37). Only 44 out of 397 (11%) samples resulted to
be misclassified. Then, the significance of the intersection
between our signatures and publicly available ones was
evaluated by a Fisher’s exact test. The signatures used for
this test were obtained from MSigDB (38) plus a specific
one derived from (39). The proliferation signatures were
added to test the TNBC subtype, known to be associated
to a strong proliferative signal. Highly significant P-values
were obtained for the intersection between our newly
defined signatures and previously published ones for the
same breast cancer subtypes. The above results confirm
the classification performances and reliability of the breast
cancer signatures here constructed.
From single miRNA to clusters of miRNAs: ClustMMRA
TheMMRA pipeline is here extended to search for genom-
ically co-clustered miRNAs potentially driving cancer sub-
typing. Similar to MMRA, the workflow of ClustMMRA
(see Figure 1) consists of subsequent filtering steps: (i) dif-
ferential expression analysis of clustered miRNAs; (ii) tar-
get enrichment analysis and (iii) network analysis. While a
miRNA cluster is usually transcribed as a single unit (40–
44), the expression of mature miRNAs in the same cluster
might not be highly correlated due to regulatory events in
the maturation processes (40,43). ClustMMRA is available
at https://github.com/lcan88/clustMMRA.
Clusters of miRNAs are identified based on their ge-
nomic organization as reported in Methods. In step (i), the
subtype-specific expression of each miRNA is assessed by
Kolmogorov–Smirnov (KS) statistical test and fold change
cutoff. Clusters having at least two miRNAs with subtype-
specific expression change in the same direction (both up-
regulated or down-regulated) are selected for step (ii).
In step (ii), we extract miRNA clusters having their pre-
dicted targets enriched for the gene signature of the corre-
sponding subtype. Only miRNAs of the cluster classified
as differentially expressed in step (i) are considered in step
(ii). The targets of individual miRNAs have been predicted
using four different databases (TargetScan 7.1, doRiNA-
PicTar 2012, microRNA.org 2010, PITA 2007) plus an ex-
perimental one (miRTarBase 2.5) and requiring the predic-
tion by at least two of them. Changes in the results of the
pipeline when the correlation between the expression pro-
files of the predictedmiRNA-target interactions is also used
are reported in Supplementary Text. The set of targets of
a cluster has been defined as the union of the targets of
individual miRNAs. To control the number of false pos-
itive results we defined a threshold for the significance of
the overlap between the targets of the cluster and the genes
present in the signature based on a null model. For 1000
times random set of genes of the same size of the set of tar-
gets are generated and tested for their intersection with the
gene signature. The 95th percentile of the obtained distri-
bution is used as threshold. The objective of step (i) and (ii)
is to identify co-clustered and co-expressed miRNAs po-
tentially regulating a gene expression signature in a joint
manner, without necessarily having a high overlap in terms
of target genes (22). Finally, in step (iii) a miRNA–mRNA
interaction network is constructed for each selected clus-
ter using the ARACNE algorithm (45,46) and employing
all the expressed genes. In this step, we identify modules of
co-clustered miRNAs and interacting genes, including in-
direct interactions, that are believed to participate in the
phenotype of a given cancer subtype (we call these mod-
ules regulons). Unlike the results of the MMRA pipeline, in
which regulons can include only one miRNA, the ones iden-
tified by the ClustMMRA pipeline contain multiple miR-
NAs of the genomic cluster. Interference of indirect inter-
actions may introduce links between miRNAs and spuri-
ous genes in the regulon. A Fisher’s exact test has been per-
formed to evaluate the statistical significance of the overlap
between the genes included in each regulon and the gene sig-
nature of the associated subtype.
Cell culture and miRNA modulation
For in vitro studies, we used two human BC epithelial cell
lines: T47D and MDA-MB-231 cells (ICLC-Biologic Bank
and Cell Factory, Italy). These cell lines were chosen as they
represent amodel of luminal A and TNBC cell lines, respec-
tively (47). Following the manufacturer’s recommendation,
wemaintained the cell lines within a humidified atmosphere
containing 5% CO2 at 37◦C in DMEM (for T47D cell line)
or advanced DMEM (for MDA-MB-231 cell line) cell cul-
ture medium (Gibco, Life Technologies), with 10% fetal
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bovine serum (FBS), 1% penicillin-streptomycin, 2mMglu-
tamine (all from Lonza, Euroclone). Dulbecco phosphate-
buffered saline (D-PBS), trypsin, and all themedia additives
were obtained by Lonza (Euroclone).
The sense (S) oligonucleotide sequence of each miRNA
of the cluster has been designed following the sequences in-
dicated in miRbase database (29). S oligonucleotides were
purchased from Sigma.
To obtain the upregulation of each miRNA, S oligonu-
cleotides, resuspended in water, were added three times a
day for 3 days directly to the culture medium of the cells
(<50% confluency) at a final concentration of 100 nM/day
(48). The cells were collected 24, 48 or 72 h of treatment and
different assays were performed (proliferation, real time-
PCRanalysis ofmiRNAs andEMTgenes andECMassay).
Proliferation assay
Tumor cell proliferation was assessed by following the pro-
tocol described in (49). Briefly, cells were seeded at a con-
fluency of 80 000 cells/w in 24-well plates. The cells were
added daily with 100 nM final concentration of S miR-214,
-199a-3p, -199a-5p. The proliferation assay was performed
either counting the cells at 24, 48 and 72 h of treatment or
by staining the alive cells with thiazolyl blue tetrazolium
bromide (MTT, SIgma Aldrich), following supplier’s sug-
gestions. The cell absorbance was counted at 540 nm at in-
dicated time points. A graphic representation of the counts
was obtained by plotting the average value of Absorbance
at each time point of three independent experiments, per-
formed in triplicate (n = 9).
ECM assay
For extracellular matrix (ECM) staining, cells were grown
for 3 days before fixation with 100% cold methanol at –
20◦C (Sigma). Then, cells were permeabilised with 0.1%
Triton X-100 (Euroclone, Italy) in PBS 1× before stain-
ing with anti-collagen I (Aurogene, Italy; 1:100). Anti rab-
bit 488 (AlexaFluor, Life Technologies) secondary antibody
was used for the staining. Images were acquired using a Le-
ica DMIL microscope (4×, 10×, 20×, 40× objectives) with
Leica ICC50W camera. Images were quantified with ‘cor-
rected total cell fluorescence (CTCF) method’, where the
integrated density was subtracted with the area of selected
cellsmultiplied for themean fluorescence of the background
readings (50,51).
RNA isolation, reverse transcription and RT-PCR analysis
Total RNA was isolated using TRIzol reagent (Life Tech-
nologies) following the manufacturer’s recommendations.
To obtain cDNA from total RNA for gene expression anal-
ysis, twomicrograms of total RNAwere reverse transcribed
using oligo dT primers in combination with High Capacity
cDNA Reverse Transcription kit (Applied Biosystem), fol-
lowing the manufacturer’s protocol.
For miRNA analysis, one microgram of total RNA was
reverse transcribed using MystiCq microRNA cDNA syn-
thesis kit (Sigma), following the manufacturer’s protocol,
in order to reverse transcribe polyA-tailed miRNA into
cDNA.
RT-PCR analysis was performed using Power Up Sybr
Green Master mix (Applied Biosystem, Life Technologies)
in an Eco RT-PCR machine (Illumina). All the primers for
humanmRNAandmiRNAamplificationwere home-made
and are described below (Supplementary Table S1).miRNA
amplification was performed using primers designed on the
mature miRNA sequence taken from miRbase v18.
The relative expression of miRNAs and genes was calcu-
lated for both T47D and MDA-MB-231 cell lines with the
2(−CT) method (52). Experiments were performed three
times in triplicate (n = 9). A t test was calculated.
RESULTS
Identification of regulatory miRNA clusters underlying
breast cancer subtypes
We applied ClustMMRA (https://github.com/lcan88/
clustMMRA) to identify polycistronic miRNAs un-
derlying breast cancer molecular subtypes. For this
study, two independent datasets were used, a first paired
miRNA/mRNA expression dataset from a in-house cohort
of 129 breast carcinoma tumour samples (which we refer
to as Curie dataset (53,54) and a second dataset from The
Cancer Genome Atlas project composed of 397 samples
(55). In both datasets, individual samples were assigned to
four subtypes (luminal A, luminal B, HER2+ and triple
negative) based on the immunohistochemical staining of
estrogen (ER), progesterone (PR) and HER-2 (ERBB2)
receptors.
ClustMMRA application to Curie and TCGA datasets
Expression data required for running ClustMMRA were
pre-processed as described in Methods and the signatures
for breast cancer subtypes were defined using the approach
proposed in (34) (see Methods). We applied the Clust-
MMRA pipeline on Curie and TCGA datasets separately.
In the first step, genomically co-clustered miRNAs having a
subtype-specific expression were identified. In this step, 28
and 47 out of 131 analyzed clustered miRNAs were selected
for Curie and TCGA datasets, respectively (see Supplemen-
tary Table S2). Of these, 18 clusters were in common be-
tween the two datasets (P-value< 7e–04), revealing a signif-
icantly concordant expression pattern of co-clustered miR-
NAs. Among these co-clustered and co-expressedmiRNAs,
some are differentially expressed in multiple subtypes (18
and 37 clusters for Curie and TCGA respectively), with 15
out of 18 and 21 out of 37 differentially expressed in TNBC
and luminal A with opposite sign.
In step (ii), 10 out of 28 (Curie) and 16 out of 47 (TCGA)
subtype-specific miRNA clusters were found to have their
predicted targets enriched in genes belonging to the corre-
sponding gene signature. The output of step (ii) (see Sup-
plementary Table S3) has an intersection of 7 elements be-
tween the two datasets (P-value< 1e–05). In the step (iii) of
ClustMMRA, a regulon for each miRNA cluster selected in
step (ii) was constructed. As expected, in the constructed
regulons, the miRNA targets tend to have a significantly
higher Mutual Information with the miRNA in respect to
the other non-target genes (see Supplementary Figure S1).
The regulons were tested for enrichment in gene signature.
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Table 1. Clusters of miRNAs identified by ClustMMRA in breast cancer TCGA and/or Curie datasets
Cluster of miRNAs
Chromosome
position
Number of
deregulated
miRNAs in the
cluster
Cluster
expression in
subtypes
Gene signature
expression in
subtypes Dataset results Also in CRC
miR-199a/214 Chr1 3 Down in TNBC Up in TNBC Curie and TCGA no
miR-493/136 Chr14 8 Down in TNBC Up in TNBC Curie and TCGA no
miR-379/656 Chr14 42 Down in TNBC Up in TNBC Curie and TCGA yes
miR-512/373 Chr19 46 Up in TNBC Up in TNBC Curie and TCGA yes
miR-532/502 ChrX 8 Up in TNBC Down in TNBC Curie and TCGA no
miR-449a/449c Chr5 3 Down in TNBC Down in TNBC TCGA no
miR-653/489 Chr7 2 Down in TNBC Down in TNBC TCGA yes
miR-548aa/548d Chr8 2 Up in TNBC Down in TNBC TCGA no
miR-421/374c ChrX 3 Up in TNBC Up TNBC TCGA yes
miR-99a/let-7c Chr21 2 Down in TNBC Up TNBC Curie no
miR-450b/424 ChrX 6 Down in TNBC Up TNBC Curie yes
Seven out of 10 and 9 out of 16 clusters passed this last
selection step in Curie and TCGA datasets, respectively.
These clusters constitute the final output of ClustMMRA
and are reported in Table 1. After this last step, the output
in common between the two datasets contains five clusters
(P-value < 8e–06). The significant overlap between results
obtained from the analysis of two independent datasets with
ClustMMRA supports the high reproducibility across in-
dependent datasets of this approach. Notably, the results
have an intersection with increasing statistical significance
at each step of the pipeline. This trend confirms the accu-
racy of the proposed pipeline in selecting candidate clusters
underlying cancer subtypes.
Some results obtained with ClustMMRA in the breast
cancer study have already been validated in the literature.
MiR-493/136 and miR-379/656 clusters in the chromoso-
mal region 14q32 have been reported as tumor suppressors
in different types of human cancer (56–58), including breast
cancer (59). Silencing of multiple miRNAs encoded in these
clusters was shown to increase the proliferation and inva-
sion of ovarian (60), melanoma (61) or oral squamous carci-
noma (56) cells. The X-chromosome-located miR-532/502
cluster has been previously associated to cancer. In partic-
ular, this was found up-regulated in triple-negative breast
cancer cells (62) and the regulatory circuit miR-502/H4K20
methyltransferase SET8 was described as a key regulator of
breast cancer pathobiology (63).
Half of the identified miRNA clusters are cancer-type specific
Multiple studies have identified miRNAs associated with
tumor development and progression in most major cancer
types (64–66). To test whether some of the clusters identi-
fied by clustMMRA in breast cancer have a driving role also
in other cancer types we repeated the analysis in Colorec-
tal Cancer (CRC). We considered in particular the paired
microRNA-MRNA expression dataset of 450 samples used
in (27). As in (27), the samples were partitioned into sub-
types according to the CRCA classifier (34). At step (i) 19
clusters were found to be differentially expressed across the
CRCA subtypes (see Supplementary Table S4). Of them, 18
were also found to have a significant number of targets in
the corresponding gene signatures (see Supplementary Ta-
ble S5). Finally, nine clusters constituted the output of clust-
MMRA in CRC (see Supplementary Table S6).
We then tested the overlap between the output of Clust-
MMRA in CRC and in breast cancer. Approximately 50%
of the clusters output of clustMMRA in breast are also
present in CRC (four out of nine in TCGA and three out of
seven in Curie) indicating that many of the identified clus-
ters of miRNAs have a regulatory role across multiple can-
cer types.
Comparison of ClustMMRA with the pipeline for the identi-
fication of single master miRNA regulators (MMRA)
We compared the results of ClustMMRA in breast and col-
orectal cancer with those obtained by applying to the same
datasets the MMRA pipeline for the identification of single
master miRNA regulators. The goal is to investigate if the
regulatory effect of a cluster can be detected by studying the
effect of individual miRNAs belonging to the same cluster.
We applied MMRA to the Curie and colorectal can-
cer (TCGA) datasets, using in each step the same thresh-
olds employed for ClustMMRA. If at least two miRNAs
of a given cluster are included in the output of MMRA,
we consider this cluster as detected in the single-miRNA
pipeline. Interestingly, four out of seven clusters detected by
ClustMMRA (miR-199a/214, miR-493/136, miR-512/373
and miR-450b/424) were not detected byMMRA in Curie.
Concerning CRC, seven out of nine miRNA clusters de-
tected by clustMMRA are lost in MMRA.
This difference between the outputs of the two pipelines
is given by the target enrichment analysis in step (ii) and the
network analysis in step (iii). In fact, the four clusters miss-
ing in the final output of MMRA in Curie are included in
the output of step (i), since they have at least two differen-
tially expressed miRNA genes. They are filtered out in step
(ii) since no miRNA gene in these clusters, when analyzed
individually, reaches a significant enrichment of signatures
genes in its targets for a certain subtype. This observation
supports the hypothesis that co-clustered miRNAs partici-
pate in regulating the gene expression signature of a given
cancer subtype without necessarily having a high overlap in
terms of common target genes.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/5/2205/5290485 by guest on 21 Septem
ber 2019
2210 Nucleic Acids Research, 2019, Vol. 47, No. 5
Figure 2. Pathways controlled by the deregulated miRNA clusters. A summary of the main biological functions controlled by the different miRNA clusters
is here reported. Y-axis of the radarplot corresponds to the sum of the absolute log(P-value) of all the pathways associated to a given function.
Prioritization of miRNA clusters for functional validation in
cell lines
Before experimental validation of the ClustMMRAoutput,
prioritization of results was performed. We considered the
five clusters identified both in TCGA and Curie datasets.
For the regulons associated to each cluster, the nodes present
in both TCGA and Curie datasets were kept, obtaining
a network for each regulon with size of about 100 nodes.
Then, biological processes and pathways associated to these
regulons were identified through Fisher’s exact enrichment
test, using MSigDB (38) as reference collection of signa-
tures for pathways and biological functions. The complete
list of MSigDB pathways resulting from this analysis (FDR
< 0.05) is reported in Supplementary Table S7.
As summarized in Figure 2, the network analysis shows
a regulation of EMT, stemness and extracellular matrix by
clusters miR-493/136, miR-379/656 and miR-199a/214.
Cluster miR-532/502 is predicted to regulate prolifera-
tion and the cell cycle transition from G to M phases.
All the regulons have been found associated to breast
cancer specific signatures, with clusters miR-493/136,
miR-379/656 and miR-199a/214 sharing nine of them
(‘SCHUETZ BREAST CANCER DUCTAL INVAS
IVE UP’,‘FARMER BREAST CANCER CLUSTER
4’,‘TURASHVILI BREAST LOBULAR CARCINO
MA VS LOBULAR NORMAL DN’,‘CHARAFE B
REAST CANCER LUMINAL VS MESENCHYMAL
DN’,‘LANDIS BREAST CANCER PROGRESSION
DN’,‘LANDIS ERBB2 BREAST TUMORS 324 D
N’,‘LIEN BREAST CARCINOMA METAPLASTIC
’,‘TURASHVILI BREAST DUCTAL CARCINOMA
VS DUCTAL NORMAL UP’,‘TURASHVILI BRE
AST LOBULAR CARCINOMA VS DUCTAL NOR
MAL UP’,‘TURASHVILI BREAST LOBULAR CAR
CINOMA VS LOBULAR NORMAL DN’). Invasive
and mesenchymal state signatures confirm the association
of these clusters to the TNBC subtype. Other general
processes were found enriched in the regulons of these
clusters: EMT (including the ‘HALLMARK EPITHEL
IAL MESENCHYMAL TRANSITION’ signature and
multiple GO terms related to the extracellular matrix),
stemness (‘BOQUEST STEM CELL UP’,‘LIM MAM
MARY STEM CELL UP’,‘IZADPANAH STEM C
ELL ADIPOSE VS BONE DN’ signatures), cell cycle
(‘IGLESIAS E2F TARGETS UP’) and angiogenesis
(‘GO VASCULATURE DEVELOPMENT’,‘GO CIR
CULATORY SYSTEM DEVELOPMENT’). Finally,
the regulon of cluster miR-532/502 was found enriched
in some breast cancer specific signatures clearly linking
it to the TNBC subtype (‘SOTIRIOU BREAST CAN
CER GRADE 1 VS 3 UP’,‘FARMER BREAST CAN
CER BASAL VS LULMINAL’ and ‘POOLA INVAS
IVE BREAST CANCER UP’). Also, it was observed
to be strongly associated to proliferation signatures (e.g.
‘ZHOU CELL CYCLE GENES IN IR RESPONSE 2
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Figure 3. In vitro analysis of miRNA modulation effect on MDA-MB-231 cells proliferation. MDA-MB-231 cells were treated for 24,48,72 hours (h)
with sense (S) oligonucleotide encoding for miRNA cluster or single miRNA (miR-214, miR-199a-5p, miR-199a-3p) or a scramble miRNA. The effect of
miRNAmodulation on cell proliferation is shown. Average±sd of three independent experiments for each cell line are shown. t-test P-value < 0.001 (***),
<0.01 (**), <0.05 (*).
Figure 4. Effect of miRNA modulation on EMT marker genes. MiRNA modulated MDA-MB-231 cells were used for RT-PCR analysis of EMT marker
genes. RT-PCR analysis shows the effect of single miRNA or miRNA cluster modulation vs scramble oligonucleotide treated cells on E-cadherin (A),
beta-catenin (B) and slug (C). Average±sd of three independent experiments for each cell line are shown. t-test P-value <0.01 (**), <0.05 (*).
4HR’,‘GO MITOTIC NUCLEAR DIVISION’,‘GO M
ITOTIC CELL CYCLE’,‘GO CHROMOSOME SEG
REGATION’,‘GO CELL DIVISION’,‘GO CELL CYC
LE PROCESS’,‘CHANG CYCLING GENES’).
Functional validation of miR-199a/miR-214 cluster in breast
cancer cell lines
To functionally validate our in silico results we considered
miR-199a/miR-214 cluster, predicted to regulate TNBC ac-
cording to clustMMRA. Considering the technical diffi-
culty in producing the over-expression of multiple miRNAs
in cell lines, we chose this cluster being the smallest of our
output. Given that miR-199a/miR-214 is underexpressed
in TNBC, its overexpression in a TNBC cell line should
make the cell shift away from the TNBC subtype. We used
as a measure to evaluate such a shift proliferation, in fact
TNBCs are known to have a higher proliferation index than
the other breast cancer subtypes (67).
MiR-199a/miR-214 cluster is underexpressed in TNBC cells.
Human miR-199a/miR-214 cluster is encoded by a large
non-coding RNA on chromosome 1q24 which produces
three mature miRNAs (hsa-miR-199a-5p, hsa-miR-199a-
3p and hsa-miR-214). First, we examined by quantitative
RT-PCR the expression of the individual mature miRNAs
belonging to this cluster in T47D and MDA-MB-231 cells,
which are luminal A and TNBC cells respectively (47). Re-
sults show that the three mature miRNAs encoded by the
miR-199a/miR-214 cluster are significantly underexpressed
in MDA-MB-231 compared to T47D cells (Supplementary
Figure S2).
Upregulation of miR-199a/miR-214 cluster decreases TNBC
cell proliferation. To test whether the deregulation of miR-
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Figure 5. Extracellular matrix (ECM) immunofluorescence assay: colla-
gen I staining. Average of the values of fluorescence intensity of Collagen
I (Col I) of single cells, after background correction. Col I immunofluo-
rescence was performed and pictures were taken at the same exposure (1 s)
and gain (6.8). Themore representative pictures for each sample are shown
(A). Single picture fluorescence intensity was quantified by ImageJ analysis
software (n = 6 images for each sample), and CTCF method was applied
and quantified (B) (t test n = 6, P value < 0.05, *; P value < 0.01, **).
199a/miR-214 cluster was sufficient to impact TNBC cells
phenotype, MDA-MB-231 cells were treated with sense (S)
oligonucleotides encoding for all the three miRNAs of the
cluster (miR-214, miR-199a-5p, miR-199-3p) or scramble
negative controls. We checked the overexpression of each
miRNA of the cluster after transfection by RT-PCR analy-
sis, shown in Supplementary Figure S3. After confirming
the upregulation of single miRNA or all three miRNAs
of the cluster in MDA-MB-231, we analyzed the effect of
miRNA overexpression on proliferation: individual miR-
NAs, except miR-199a-3p, and entire miR-199a/miR-214
cluster overexpression reduce the MDA-MB-231 cell num-
ber compared to scramble or untreated control (Figure 3).
We then focused on the regulation of EMT predicted by
clustMMRA (see Figure 2) as an interesting phenotype to
validate in TNBC subtype.
MiR-199a/miR-214 cluster silencing is associated with
EMT-like and invasive phenotype. According to our re-
sults, miR-199a/miR-214 cluster is also predicted to mod-
ulate EMT genes and cell invasion. To investigate if the
expression of this cluster affects the molecular profile of
the cells, we analyzed the expression levels of EMT-related
genes upon upregulation of a singlemiRNAof the cluster or
the whole cluster through S oligonucleotide treatment. We
observed a reduction of EMTmarker genes upon both indi-
vidual miRNAs or entire miR-199a/miR-214 cluster over-
expression (Figure 4), as demonstrated by the increase ex-
pression of epithelial markers E-cadherin and Beta-catenin
and a decrease of the expression level of the mesenchymal
marker Slug.
As a negative control we repeated the same experiment on
miR-502/532 cluster also associated by clustMMRA to the
TNBC subtype. This cluster was predicted to control pro-
liferation, but not EMT (see Figure 2). As shown in Sup-
plementary Figures S4 and S5 our experiments confirm the
predictions of clustMMRA.
Finally, to further confirm the regulation of EMT by
miR-199a/miR-214 cluster, we evaluated its modulatory ef-
fect on the ExtracellularMatrix (ECM).We thus performed
an ECM assay in cells overexpressing miR-214, miR-199a-
5p, miR-199a-3p alone or the cluster. This assay consists in
the analysis of the effect ofmiRNAoverexpression onECM
deposition by immunofluorescence of one component of the
extracellular matrix (in our case collagen 1, Col1). Some
representative pictures for each sample are shown in Figure
5A. In Figure 5B we quantified the signal emitted by the
immunofluorescence using the CTCF method described in
(50,51). Both miR-214 alone or in combination with miR-
199a within the cluster decreased significantly the deposi-
tion of ECM protein components (Col1), suggesting that
the components of the cluster specifically control the depo-
sition of the proteins of the ECM.
DISCUSSION
Over the last two decades there has been an explosion of
research focused on miRNAs involvement in cancer initi-
ation and progression, pointing out the potential of these
small RNAs as biomarkers for diagnosis, prognosis and re-
sponse to treatment. However, the majority of computa-
tional and experimental approaches for the identification of
mastermiRNA regulators involved in cancer onset and sub-
typing are typically designed to detect the regulatory effect
of a single miRNA. This can be a limitation in identifying
regulation by multiple miRNA species acting cooperatively
on cellular pathways and pathological changes.
The computational pipeline here described, Clust-
MMRA, was specifically designed to search for genomi-
cally clustered miRNAs potentially driving cancer subtyp-
ing. ClustMMRA provides a computational framework to
systematically investigate polycistronic miRNA transcripts
involved in cancer subtyping or possibly in other biolog-
ical contexts. In practice, the use of ClustMMRA can be
generalized in order to study other classes of cooperatively
acting miRNAs than the case of genomic clusters, such as
co-expressed miRNAs from different genomic locations.
In our study, ClustMMRA was applied to search for
oncogenic / tumour suppressor polycistronicmiRNAs driv-
ing breast cancer subtypes, pointing out five novel miRNA
clusters whose regulatory effect is potentially associated to
the triple negative subtype phenotype. Among them, the
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miR-199/miR-214 is identified as acting on EMT in TNBC
subtype. Our computational and experimental validation
of the regulatory effect of miR-199/miR-214 show that the
down-regulation of this genomic cluster is associated to ap-
pearance of EMT-like phenotype in the TNBC cells. The
upregulation of individualmiRNAs belonging to the cluster
or the entire cluster decreases the expression of a marker of
mesenchymal phenotype (i.e. Slug) and increases the expres-
sion of epithelial markers (E-cadherin and beta-catenin).
The effects on EMTobtained by the overexpression ofmiR-
199/miR-214 cluster are further confirmed by its control on
the deposition of the ECMproteins. Our results suggest that
this cluster of miRNAs is possibly involved in the mainte-
nance of more aggressive phenotypes of breast cancer, by
regulating EMT target genes, and cell proliferation. Finally,
our study supports the hypothesis of miRNA cooperativ-
ity from a polycistronic transcript as a possible mechanism
of joint targeting to act on molecular pathways involved
in cancer malignancy and subtyping. More accurate mea-
surements and quantitative study might improve the under-
standing of these cooperative effects.
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